Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanley Schwartz

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Postgraduate Medicine|June 12, 2014
Evidence-based practice use of incretin-based therapy in the natural history of diabetesStanley Schwartz
Current Medical Research and Opinion|October 3, 2008
Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatideStanley Schwartz
Archives of Pathology & Laboratory Medicine|February 5, 2002
Dutcher bodies in chronic synovitisYulia Gray, Stanley Schwartz
Postgraduate Medicine|April 28, 2015
Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategiesStanley Schwartz, Mary Herman
Anesthesiology Clinics|April 20, 2010
How to manage perioperative endocrine insufficiencyBenjamin A Kohl, Stanley Schwartz
The Medical Clinics of North America|August 12, 2009
Surgery in the patient with endocrine dysfunctionBenjamin A Kohl, Stanley Schwartz
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|March 26, 2011
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapiesStanley Schwartz, Benjamin A Kohl
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|August 8, 2014
Use of incretin-based therapy in hospitalized patients with hyperglycemiaGuillermo E Umpierrez, Stanley Schwartz
Diabetes Care|January 25, 2014
Response to comment. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?Stanley Schwartz, Ralph A Defronzo
Diabetes Care|June 27, 2013
Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: The time has come for GLP-1 receptor agonists!Stanley Schwartz, Ralph A DeFronzo
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Postgraduate Medicine|June 12, 2014
Evidence-based practice use of incretin-based therapy in the natural history of diabetesStanley Schwartz
Current Medical Research and Opinion|October 3, 2008
Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatideStanley Schwartz
Archives of Pathology & Laboratory Medicine|February 5, 2002
Dutcher bodies in chronic synovitisYulia Gray, Stanley Schwartz
Postgraduate Medicine|April 28, 2015
Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategiesStanley Schwartz, Mary Herman
Anesthesiology Clinics|April 20, 2010
How to manage perioperative endocrine insufficiencyBenjamin A Kohl, Stanley Schwartz
The Medical Clinics of North America|August 12, 2009
Surgery in the patient with endocrine dysfunctionBenjamin A Kohl, Stanley Schwartz
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|March 26, 2011
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapiesStanley Schwartz, Benjamin A Kohl
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|August 8, 2014
Use of incretin-based therapy in hospitalized patients with hyperglycemiaGuillermo E Umpierrez, Stanley Schwartz
Diabetes Care|January 25, 2014
Response to comment. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?Stanley Schwartz, Ralph A Defronzo
Diabetes Care|June 27, 2013
Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: The time has come for GLP-1 receptor agonists!Stanley Schwartz, Ralph A DeFronzo
Pageof 4